Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024

Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024

This article profiles 27 innovative advancements in small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) in 2024. These drugs target various therapeutic areas including non-small cell lung cancer, advanced or metastatic breast cancer, glioma, relapsed or refractory acute leuk...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhonglei Wang, Xin Sun, Mingyu Sun, Chao Wang, Liyan Yang
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Pharmaceuticals
Subjects:	innovative advancements small molecule drugs FDA first-in-class breakthrough therapies
Online Access:	https://www.mdpi.com/1424-8247/18/5/729
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Global first-in-class drugs approved in 2023–2024: Breakthroughs and insights
by: Daichao Zhai, et al.
Published: (2025-04-01)

Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023-11-01)

Original drugs approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2024
by: D. V. Kurkin, et al.
Published: (2025-07-01)

2024 FDA TIDES (Peptides and Oligonucleotides) Harvest
by: Othman Al Musaimi, et al.
Published: (2025-02-01)

Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease
by: Israa J. Hakeem, et al.
Published: (2025-05-01)

Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015–2024)
by: Moutaz W. Sweileh
Published: (2025-08-01)

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
by: Triana Amen, et al.
Published: (2016-03-01)

Regulatory landscape of accelerated approval pathways for medical devices in the United States and the European Union
by: Tanvi Gupte, et al.
Published: (2025-05-01)

In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
by: Ridwan Abiodun Salaam, et al.
Published: (2025-03-01)

Activity of soil fluorescein diacetate (FDA) hydrolase under long-term fertilization
by: MA Xing-zhu
Published: (2010-07-01)

A Search for FDA Approved Drugs with Multiple Antiemetic Targets: A Computational-Based Drug Repositioning Study
by: Abdulmajeed Yunusa*1, Albashir Tahir1,2
Published: (2025-05-01)

A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational Study
by: Ajay Kumar Shukla, et al.
Published: (2025-01-01)

A Computational Study of Efficient Combinations of FDA-Approved Drugs and Dietary Supplements in Endometrial Cancer
by: Madhurima Mondal, et al.
Published: (2024-01-01)

FDA-approved kinase inhibitors in PROTAC design, development and synthesis
by: Kacper Kossakowski, et al.
Published: (2025-12-01)

FDA approves leniolisib (Joenja) as the first treatment for APDS: A breaththrough in the field of immunology
by: Muhammad Talha, et al.
Published: (2024-01-01)

Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases <i>Pseudomonas aeruginosa</i> Tolerance to Ciprofloxacin
by: Yael Schlichter Kadosh, et al.
Published: (2024-11-01)

Transformative Advances in Continuous Glucose Monitoring and the Impact of FDA Over‐the‐Counter Approval on Diabetes Care
by: Zain Afridi, et al.
Published: (2025-04-01)

In Silico Study of FDA-Approved Drugs on <i>Leishmania infantum</i> CYP51, a Drug Repositioning Approach in Visceral Leishmaniasis
by: Juan Diego Guarimata, et al.
Published: (2024-11-01)

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve
by: Sarfaraz K. Niazi
Published: (2024-12-01)

A realworld pharmacovigilance study of trazodone based on the FDA adverse event reporting system
by: Yong Yu, et al.
Published: (2025-02-01)

FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry
by: Manisha Singh, et al.
Published: (2025-03-01)

Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
by: Saumya Choudhary, et al.
Published: (2025-07-01)

Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
by: Lele Ge, et al.
Published: (2025-05-01)

The ladder of regulatory stringency and balance: an application to the US FDA’s regulation of bacterial live therapeutics
by: Moshe Maor, et al.
Published: (2025-12-01)

In Silico Investigation of TATA-Binding Protein as a Therapeutic Target for Chagas Disease: Insights into FDA Drug Repositioning
by: Carlos Gaona-López, et al.
Published: (2025-06-01)

Analyzing FDA's approaches to using electronic health record and medical claims data to support regulatory decision making
by: Ksenia S. Radaeva, et al.
Published: (2023-10-01)

Cognitive FDA-MIMO Radar Network’s Transmit Element Selection Algorithm for Target Tracking in a Complex Interference Scenario
by: Yingfei Yan, et al.
Published: (2024-12-01)

Multiresolution FDA-SAR Imaging Method Based on Sub-band Shifting
by: Keyi WANG, et al.
Published: (2025-06-01)

Spontaneous nanoemulsification for solubility enhancement of BCS class II and IV molecules, quercetin as a model drug
by: Marwan Motuq Alsufyani, et al.
Published: (2025-06-01)

Clinical and microbiological analysis of risk factors for breakthrough bloodstream infection during Tigecycline Therapy
by: Sol Jin, et al.
Published: (2025-02-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

The Dependence of Water and Gas Breakthrough on the Choice of Model Parameters in Naturally Fractured Reservoirs Using Sector and Full Reservoir Models
by: Barham Sabir Mahmood, et al.
Published: (2024-05-01)

BREAKTHROUGH ECONOMY: FEATURES OF FORMATION AND DEVELOPMENT IN RUSSIA
by: E. Bykovskaia, et al.
Published: (2019-11-01)

The Second Wave of the COVID-19 Pandemic in Poland - Characterised Using FDA Methods
by: Patrycja Hęćka
Published: (2023-02-01)

Drug-induced cardiac arrest: a pharmacovigilance study from 2004–2024 based on FAERS database
by: Gaocan Ren, et al.
Published: (2025-05-01)

Patient-reported outcome claims in European and United States orphan drug approvals
by: Szymon Jarosławski, et al.
Published: (2018-01-01)

New Drug Approvals in China: An International Comparative Analysis, 2019-2023
by: Yan Y, et al.
Published: (2025-04-01)

Generalized Ambiguity Function for Bistatic FDA Radar Joint Velocity, Range, and Angle Parameters
by: Xuchen Gao, et al.
Published: (2025-05-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
by: Akimasa Sanagawa, et al.
Published: (2018-06-01)